PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
31.20%
Revenue growth above 1.5x CSIQ's 8.66%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
-78.20%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-1010.38%
Negative EBIT growth while CSIQ is at 15.52%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-7584.19%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-6871.81%
Negative net income growth while CSIQ stands at 20.50%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-6763.64%
Negative EPS growth while CSIQ is at 14.29%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-6763.64%
Negative diluted EPS growth while CSIQ is at 23.08%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
1.25%
Share count expansion well above CSIQ's 0.41%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.25%
Slight or no buyback while CSIQ is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
39.38%
OCF growth of 39.38% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
41.08%
FCF growth of 41.08% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
551.36%
10Y revenue/share CAGR under 50% of CSIQ's 12495.67%. Michael Burry would suspect a lasting competitive disadvantage.
610.09%
5Y revenue/share CAGR under 50% of CSIQ's 1225.10%. Michael Burry would suspect a significant competitive gap or product weakness.
25.83%
3Y revenue/share CAGR at 50-75% of CSIQ's 47.75%. Martin Whitman would question if the firm lags behind competitor innovations.
-200.41%
Negative 10Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-1610.30%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-387.08%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-320.95%
Negative 10Y net income/share CAGR while CSIQ is at 1130.90%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1901.08%
Negative 5Y net income/share CAGR while CSIQ is 206.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-485.94%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
110.96%
Below 50% of CSIQ's 1375.71%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
25.32%
3Y equity/share CAGR at 50-75% of CSIQ's 44.98%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
58.28%
AR growth well above CSIQ's 2.30%. Michael Burry fears inflated revenue or higher default risk in the near future.
-15.35%
Inventory is declining while CSIQ stands at 42.82%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-3.92%
Negative asset growth while CSIQ invests at 26.59%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-9.42%
We have a declining book value while CSIQ shows 2.22%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-4.16%
We’re deleveraging while CSIQ stands at 49.01%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
11.79%
R&D dropping or stable vs. CSIQ's 138.96%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
33.38%
SG&A growth well above CSIQ's 15.52%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.